A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.

John GlodFernanda I ArnaldezLori S WienerMelissa SpencerJ Keith KillianPaul MeltzerEva DombiClaudia Derse-AnthonyJoanne DerdakRamaprasad SrinivasanW Marston LinehanMarkku MiettinenSeth M SteinbergLee HelmanBrigitte C Widemann

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Vandetanib at a dose of 300 mg daily was not well tolerated by adults with dSDH GIST. Two of 9 patients had prolonged stable disease, but no partial or complete responses were observed, and vandetanib is thus not considered active in dSDH GIST.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
study protocol
wild type